August 29, 2024 11:33 AM EDT
Pharma
Manufacturing

Ahead of ac­qui­si­tion by No­vo Hold­ings, are Catal­ent’s dark days be­hind it? 

Anna Brown

News Reporter

In the months lead­ing up to its pend­ing ac­qui­si­tion by No­vo Hold­ings, Catal­ent has mean­ing­ful­ly boost­ed its rev­enue for the first time in over a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times